MG
Highly rated in
28
conditions
Highly rated in
28
conditions
Check Dr. Morie A. Gertz's experience treating your condition:
About Dr. Morie A. Gertz

Morie Gertz is a Hematologist and a Hematologist Oncology expert in Rochester, Minnesota. Gertz has been practicing medicine for over 47 years and is highly rated in 28 conditions, according to our data. His top areas of expertise are Primary Amyloidosis, Multiple Myeloma, Waldenstrom Macroglobulinemia, Bone Marrow Transplant, and Tissue Biopsy. He is licensed to treat patients in Minnesota. Gertz is currently accepting new patients.

His clinical research consists of co-authoring 678 peer reviewed articles and participating in 7 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Morie A. Gertz it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Morie A. Gertz accepts the following insurance:

  •  Ambetter
  •  Medica

Call to see if your plan is accepted.
Locations
200 1st St Sw, Rochester, MN 55905
Background & Education
Graduate Institution
Loyola University Of Chicago, Stritch School Of Medicine, 1975
Specialties
Hematology
Hematology Oncology
Licenses
Internal Medicine in MN
Hospital Affiliations
Mayo Clinic Hospital - Saint Marys Campus
Mayo Clinic Health System - Albert Lea
Mayo Clinic Health System - Cannon Falls
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

Phase I/II Study of G3139 (Genasense) in Patients With Waldenstrom's Macroglobulinemia
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
View 6 Less Clinical Trials -

678 Total Publications

Treatment of amyloid light chain cardiac amyloidosis: systematic review and future directions.


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors